CG Oncology annual return on equity
2023
2024
2025
CG Oncology Return on Equity (ROE) Growth & History (CGON)
CG Oncology's return on equity was −21.67% for fiscal 2025.
View full CG Oncology company overviewCG Oncology annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −21.67% | +7.18 pp |
| 2024 | 2024-12-31 | −28.85% | +4651.65 pp |
| 2023 | 2023-12-31 | −4,680.50% | — |
CG Oncology quarterly return on equity
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −7.45% | −1.43 pp |
| Q1 2026 | 2026-03-31 | −6.53% | −1.74 pp |
| Q4 2025 | 2025-12-31 | −5.74% | −0.73 pp |
| Q3 2025 | 2025-09-30 | −6.45% | −2.70 pp |
| Q2 2025 | 2025-06-30 | −6.03% | −2.65 pp |
| Q1 2025 | 2025-03-31 | −4.79% | +2.81 pp |
| Q4 2024 | 2024-12-31 | −5.01% | — |
| Q3 2024 | 2024-09-30 | −3.75% | — |
| Q2 2024 | 2024-06-30 | −3.37% | — |
| Q1 2024 | 2024-03-31 | −7.60% | — |
CG Oncology return on equity trends
Between the periods ended 2023-12-31 and 2025-12-31, CG Oncology's return on equity increased from −4,680.50% to −21.67%, a change of +4658.83 percentage points. The latest reported quarter, Q2 2026, shows −7.45%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review CG Oncology source filings ↗